Skip to content

Study · Non-randomized trial · 2026

10 results

Effect of Vosoritide Therapy on IGF-I and Endogenous C-Type Natriuretic Peptide in Hypochondroplasia.

Kanakatti Shankar R, Galetaki DM, Zhang A, Shafaei N, Pitner K, Seaforth R, Prickett T, Espiner EA, Dauber A

The Journal of clinical endocrinology and metabolism1 Apr 2026

PMID41157964 (opens in a new tab)DOI10.1210/clinem/dgaf591 (opens in a new tab)PepBankPUB-41157964
Publisher pagePubMedAsk about this study
Jump to 10 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study10

10 results from studies that gave the peptide. 10 results from people.

  1. 01HumanNon-randomized trialMechanism

    In children with hypochondroplasia, IGF-1 concentrations increased throughout a study with baseline observation followed by vosoritide treatment.

    In plain wordsIn children with hypochondroplasia, IGF-1 increased across a study that included observation before vosoritide treatment.

    Peptide
    Vosoritide
    Outcome
    IncreaseIGF-1 concentration
    Study

    n: not reported in source

    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    15 μg/kg/day · subcutaneousAs given in this study (human).

    Source sentences

    Summary
    Baseline IGF-1 values are reduced in children with HCH and increased throughout the study, but IGF-1 SD did not change significantly.
    2 context sentences
    Summary · context
    We hypothesized that IGF-1 and CNP will be inversely associated at baseline and will respond differentially during a single-arm, unblinded, standardized 12-month phase 2 clinical trial of vosoritide in prepubertal patients aged 3 to 11 years with HCH and height less than -2.25 SD.
    Summary · context
    Participants were followed for a baseline 6-month observation period and then received a dose of 15 μg/kg/day of vosoritide subcutaneous daily injections for 12 months.
  2. 02HumanNon-randomized trialMechanism

    In children with hypochondroplasia, IGF-1 SD did not change significantly during a study with baseline observation followed by vosoritide treatment.

    In plain wordsIn children with hypochondroplasia, IGF-1 SD did not change significantly across observation and vosoritide treatment.

    Peptide
    Vosoritide
    Outcome
    No significant changeIGF-1 SD
    Study

    n: not reported in source

    Comparator
    Baseline
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    15 μg/kg/day · subcutaneousAs given in this study (human).

    Source sentences

    Summary
    Baseline IGF-1 values are reduced in children with HCH and increased throughout the study, but IGF-1 SD did not change significantly.
    2 context sentences
    Summary · context
    We hypothesized that IGF-1 and CNP will be inversely associated at baseline and will respond differentially during a single-arm, unblinded, standardized 12-month phase 2 clinical trial of vosoritide in prepubertal patients aged 3 to 11 years with HCH and height less than -2.25 SD.
    Summary · context
    Participants were followed for a baseline 6-month observation period and then received a dose of 15 μg/kg/day of vosoritide subcutaneous daily injections for 12 months.
  3. 03HumanNon-randomized trialMechanism

    In children with hypochondroplasia, NTproCNP concentrations declined throughout a study with baseline observation followed by vosoritide treatment.

    In plain wordsIn children with hypochondroplasia, NTproCNP declined across a study that included observation before vosoritide treatment.

    Peptide
    Vosoritide
    Outcome
    DecreaseNTproCNP concentration
    Study

    n: not reported in source

    Outcome group
    Receptor activity and mechanism · Endocrine and hormones
    Studied dose
    15 μg/kg/day · subcutaneousAs given in this study (human).

    Source sentences

    Summary
    NTproCNP was raised at baseline and declined throughout the study, with NTproCNP SD significantly lower at months 6 and 12 on treatment.
    2 context sentences
    Summary · context
    We hypothesized that IGF-1 and CNP will be inversely associated at baseline and will respond differentially during a single-arm, unblinded, standardized 12-month phase 2 clinical trial of vosoritide in prepubertal patients aged 3 to 11 years with HCH and height less than -2.25 SD.
    Summary · context
    Participants were followed for a baseline 6-month observation period and then received a dose of 15 μg/kg/day of vosoritide subcutaneous daily injections for 12 months.
  4. 04HumanNon-randomized trialMechanism

    In children with hypochondroplasia, NTproCNP SD was significantly lower at month 6 of vosoritide treatment than baseline.

    In plain wordsIn children with hypochondroplasia, NTproCNP SD was lower after six months of vosoritide than baseline.

    Peptide
    Vosoritide
    Outcome
    DecreaseNTproCNP SD at month 6
    Study

    n: not reported in source

    Comparator
    Baseline
    Outcome group
    Receptor activity and mechanism · Endocrine and hormones
    Studied dose
    15 μg/kg/day · subcutaneous · 6 monthsAs given in this study (human).

    Source sentences

    Summary
    NTproCNP was raised at baseline and declined throughout the study, with NTproCNP SD significantly lower at months 6 and 12 on treatment.
    2 context sentences
    Summary · context
    We hypothesized that IGF-1 and CNP will be inversely associated at baseline and will respond differentially during a single-arm, unblinded, standardized 12-month phase 2 clinical trial of vosoritide in prepubertal patients aged 3 to 11 years with HCH and height less than -2.25 SD.
    Summary · context
    Participants were followed for a baseline 6-month observation period and then received a dose of 15 μg/kg/day of vosoritide subcutaneous daily injections for 12 months.
  5. 05HumanNon-randomized trialMechanism

    In children with hypochondroplasia, NTproCNP SD was significantly lower at month 12 of vosoritide treatment than baseline.

    In plain wordsIn children with hypochondroplasia, NTproCNP SD was lower after twelve months of vosoritide than baseline.

    Peptide
    Vosoritide
    Outcome
    DecreaseNTproCNP SD at month 12
    Study

    n: not reported in source

    Comparator
    Baseline
    Outcome group
    Receptor activity and mechanism · Endocrine and hormones
    Studied dose
    15 μg/kg/day · subcutaneous · 12 monthsAs given in this study (human).

    Source sentences

    Summary
    NTproCNP was raised at baseline and declined throughout the study, with NTproCNP SD significantly lower at months 6 and 12 on treatment.
    2 context sentences
    Summary · context
    We hypothesized that IGF-1 and CNP will be inversely associated at baseline and will respond differentially during a single-arm, unblinded, standardized 12-month phase 2 clinical trial of vosoritide in prepubertal patients aged 3 to 11 years with HCH and height less than -2.25 SD.
    Summary · context
    Participants were followed for a baseline 6-month observation period and then received a dose of 15 μg/kg/day of vosoritide subcutaneous daily injections for 12 months.
  6. 06HumanObservational studyMechanism

    In children receiving vosoritide for hypochondroplasia, height SD change did not correlate with IGF-1 SD at 12 months.

    In plain wordsIn children receiving vosoritide, height SD changes were not linked to IGF-1 SD at twelve months.

    Peptide
    Vosoritide
    Outcome
    No significant changeHeight SD change and IGF-1 SD correlation
    Study

    n: not reported in source

    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    15 μg/kg/day · subcutaneous · 12 monthsAs given in this study (human).

    Source sentences

    Summary
    Change in height SD or AGV were not correlated to IGF-1 or NTproCNP SD at 12 months.
    2 context sentences
    Summary · context
    We hypothesized that IGF-1 and CNP will be inversely associated at baseline and will respond differentially during a single-arm, unblinded, standardized 12-month phase 2 clinical trial of vosoritide in prepubertal patients aged 3 to 11 years with HCH and height less than -2.25 SD.
    Summary · context
    Participants were followed for a baseline 6-month observation period and then received a dose of 15 μg/kg/day of vosoritide subcutaneous daily injections for 12 months.
  7. 07HumanObservational studyMechanism

    In children receiving vosoritide for hypochondroplasia, height SD change did not correlate with NTproCNP SD at 12 months.

    In plain wordsIn children receiving vosoritide, height SD changes were not linked to NTproCNP SD at twelve months.

    Peptide
    Vosoritide
    Outcome
    No significant changeHeight SD change and NTproCNP SD correlation
    Study

    n: not reported in source

    Outcome group
    Receptor activity and mechanism · Endocrine and hormones
    Studied dose
    15 μg/kg/day · subcutaneous · 12 monthsAs given in this study (human).

    Source sentences

    Summary
    Change in height SD or AGV were not correlated to IGF-1 or NTproCNP SD at 12 months.
    2 context sentences
    Summary · context
    We hypothesized that IGF-1 and CNP will be inversely associated at baseline and will respond differentially during a single-arm, unblinded, standardized 12-month phase 2 clinical trial of vosoritide in prepubertal patients aged 3 to 11 years with HCH and height less than -2.25 SD.
    Summary · context
    Participants were followed for a baseline 6-month observation period and then received a dose of 15 μg/kg/day of vosoritide subcutaneous daily injections for 12 months.
  8. 08HumanObservational studyMechanism

    In children receiving vosoritide for hypochondroplasia, AGV change did not correlate with IGF-1 SD at 12 months.

    In plain wordsIn children receiving vosoritide, growth velocity changes were not linked to IGF-1 SD at twelve months.

    Peptide
    Vosoritide
    Outcome
    No significant changeAGV change and IGF-1 SD correlation
    Study

    n: not reported in source

    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    15 μg/kg/day · subcutaneous · 12 monthsAs given in this study (human).

    Source sentences

    Summary
    Change in height SD or AGV were not correlated to IGF-1 or NTproCNP SD at 12 months.
    2 context sentences
    Summary · context
    We hypothesized that IGF-1 and CNP will be inversely associated at baseline and will respond differentially during a single-arm, unblinded, standardized 12-month phase 2 clinical trial of vosoritide in prepubertal patients aged 3 to 11 years with HCH and height less than -2.25 SD.
    Summary · context
    Participants were followed for a baseline 6-month observation period and then received a dose of 15 μg/kg/day of vosoritide subcutaneous daily injections for 12 months.
  9. 09HumanObservational studyMechanism

    In children receiving vosoritide for hypochondroplasia, AGV change did not correlate with NTproCNP SD at 12 months.

    In plain wordsIn children receiving vosoritide, growth velocity changes were not linked to NTproCNP SD at twelve months.

    Peptide
    Vosoritide
    Outcome
    No significant changeAGV change and NTproCNP SD correlation
    Study

    n: not reported in source

    Outcome group
    Receptor activity and mechanism · Endocrine and hormones
    Studied dose
    15 μg/kg/day · subcutaneous · 12 monthsAs given in this study (human).

    Source sentences

    Summary
    Change in height SD or AGV were not correlated to IGF-1 or NTproCNP SD at 12 months.
    2 context sentences
    Summary · context
    We hypothesized that IGF-1 and CNP will be inversely associated at baseline and will respond differentially during a single-arm, unblinded, standardized 12-month phase 2 clinical trial of vosoritide in prepubertal patients aged 3 to 11 years with HCH and height less than -2.25 SD.
    Summary · context
    Participants were followed for a baseline 6-month observation period and then received a dose of 15 μg/kg/day of vosoritide subcutaneous daily injections for 12 months.
  10. 10HumanObservational studyMechanism

    In children receiving vosoritide for hypochondroplasia, IGF-1 and NTproCNP concentration changes correlated positively at 12 months (ρ = 0.57, P = .024).

    In plain wordsIn children receiving vosoritide, IGF-1 changes were positively linked to NTproCNP changes at twelve months.

    Peptide
    Vosoritide
    Outcome
    IncreaseIGF-1 and NTproCNP concentration change correlation
    Study

    n: not reported in source

    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    15 μg/kg/day · subcutaneous · 12 monthsAs given in this study (human).

    Measurements

    Spearman correlation (rho)
    0.57
    change in IGF-1 versus change in NTproCNP at 12 months
    p-value
    0.024
    change in IGF-1 versus change in NTproCNP at 12 months

    Source sentences

    Summary
    The change in IGF-1 concentrations at 12 months was positively correlated with the change in NTproCNP plasma concentrations (ρ = 0.57; P = .024).
    2 context sentences
    Summary · context
    We hypothesized that IGF-1 and CNP will be inversely associated at baseline and will respond differentially during a single-arm, unblinded, standardized 12-month phase 2 clinical trial of vosoritide in prepubertal patients aged 3 to 11 years with HCH and height less than -2.25 SD.
    Summary · context
    Participants were followed for a baseline 6-month observation period and then received a dose of 15 μg/kg/day of vosoritide subcutaneous daily injections for 12 months.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:37 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.